The FDA cited trial design concerns and lack of substantial evidence in denying approval for Replimune’s biologics license application in advanced melanoma.

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...

AstraZeneca's Tagrisso with chemo significantly improves survival and progression-free outcomes in EGFR-mutant NSCLC, final trial data shows.

The Venice Theater is expected to fully reopen by mid-2026, marking a major milestone in the city’s ongoing recovery from ...

A significant reduction was not observed in the annualised rate of moderate or severe COPD exacerbations with tezepelumab versus placebo. Further studies are required to evaluate the efficacy of ...